C

ancer patients are locked in an intensifying struggle with insurers, who sometimes force them to try less expensive drugs before moving to more expensive ones, even against doctors’ wishes.

Now the American Society of Clinical Oncology, or ASCO, is deepening its involvement in the fight, issuing a set of recommendations Tuesday that it hopes insurers will follow as they confront a growing lineup of expensive cancer drugs.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Sign up for our
Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine — delivered straight to your inbox every weekday afternoon.